Wolters, Emma E.
Golla, Sandeep S. V.
Timmers, Tessa
Ossenkoppele, Rik
van der Weijden, Chris W. J.
Scheltens, Philip
Schwarte, Lothar
Schuit, Robert C.
Windhorst, Albert D.
Barkhof, Frederik
Yaqub, Maqsood
Lammertsma, Adriaan A.
Boellaard, Ronald
van Berckel, Bart N. M.
Funding for this research was provided by:
ZonMw
AVID pharmaceuticals
Center for Translational Molecular Medicine
Article History
Received: 22 May 2018
Accepted: 6 August 2018
First Online: 15 August 2018
Ethics approval and consent to participate
: All subjects underwent the same study protocol as described before [ CitationRef removed ]. Informed consent was obtained from all subjects. The study protocol was approved by the Medical Ethics Review Committee of the VU University Medical Center.
: Not applicable.
: This study was carried out with financial support from AVID to the VU University Medical Center. AVID contributed to the implementation and writing of the study protocol, but were not involved in the design of and analysis for this report.Golla, Wolters, Timmers, Ossenkoppele, van der Weijden, Schwarte, Schuit, Barkhof, Windhorst, Lammertsma, Yaqub, and Boellaard report no conflict of interest.Van Berckel receives research support from ZON-MW, AVID radiopharmaceuticals, CTMM and Janssen Pharmaceuticals. He is a trainer for Piramal and GE. He receives no personal honoraria.F. Barkhof is editorial board member of Brain, European Radiology, Neurology®, Multiple Sclerosis Journal, and Radiology; performed consultancy and received personal compensation and honoraria from Bayer-Schering Pharma and Genzyme; received compensation (personal and to institution) and honoraria from Biogen-IDEC, TEVA, Merck-Serono, Novartis, Roche, Synthon BV, and Jansen Research; received payment for development of educational presentations from IXICO and Biogen-IDEC (to institution); is funded by a Dutch MS Society grant, EU-FP7/H2020; and is supported by the NIH Research Biomedical Research Center at University College London Hospital.Scheltens received grant support (to the institution) from GE Healthcare, Danone Research, Piramal and MERCK. In the past 2 years, he has received consultancy/speaker fees from Lilly, GE Healthcare, Novartis, Forum, Sanofi, Nutricia, Probiodrug and EIP Pharma. All funding is paid to the institution.No other potential conflicts of interest relevant to this article exist.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.